advancing towards Phase 1/2
Elicio is developing ELI-002, an Amphiphile vaccine, to elicit a powerful immune response against mutations of the KRAS gene and ultimately stop recurrence of disease. KRAS mutations are present in 90% of pancreatic cancers, 40% of colorectal cancers, and 30% of non-small cell lung cancers. Pre-clinical in vivo models have demonstrated that ELI-002 creates a powerful T cell response by precisely targeting delivery to the lymph nodes, to maximize stimulation of the immune response.
Pancreatic cancer remains one of the most deadly cancers. Despite improvements in both neoadjuvant (before surgery) and adjuvant (following surgery) chemotherapy regimens, most patients who undergo pancreatic cancer surgery will relapse and die from their disease. A Phase 1/2 trial of ELI-002, in the adjuvant setting of operable pancreatic cancer, will be initiated in early 2020.
Colorectal cancer now accounts for 8% of cancer-related mortality in the US and despite advances in surgical and medical approaches to therapy, long term survival and cure rates have remained largely unchanged in the past several decades. A Phase 1/2 trial of ELI-002, in the adjuvant setting of operable colorectal cancer, will be initiated in 2020.
Elicio is developing ELI-001, another Amphiphile vaccine, for the treatment of HPV-driven head and neck cancers. HPV E6 and E7 protein antigens are present in 80-90% of oropharyngeal carcinoma, a common subgroup of head and neck cancers. By using the Amphiphile approach to trigger an immune response against HPV E6 and E7 antigens, preclinical studies show, lymph node-targeted vaccines elicited unprecedented anti-tumor cellular immune responses (~80% of CD8 T cells specific for the antigen) and complete eradication of large, established tumors in a majority of treated mice.